Gasporox: Close to sustained profitability
Research Update
2024-08-08
07:00
Analyst Q&A
Closed
Rasmus Jacobsson answered 3 questions.
Redeye states that Q2 2024 was solid, beating estimates across the board. Redeye is encouraged by Gasporox's product expansion and sustained profitability trajectory. Gasporox is close to achieving its sustained positive free cash flow target, which was declared concurrently with the convertible debt raised in 2022. Despite management being on track to reach its target, Gasporox trade at its lowest EV/S over the past three years, giving little credit to management’s execution. Redeye reiterates estimates and fair value range.
Rasmus Jacobsson
Martin Wahlström
Contents
Estimates versus outcome
Download article
Q2 2024 was a solid quarter, beating our estimates across the board. Gasporox delivered 19% net sales growth y/y on a tough comparison quarter while reaching positive EBIT. Q2 2024 is the eighth consecutive quarter of positive EBITDA. Although Gasporox’s convertible debt matures in Q3 2024, which may weight on the share, we believe the debt will be converted into equity considering the favourable terms (conversion price SEK8.5). We believe the company has a contingency plan in place if need be.
Following the launch of AutoMap, Gasporox launched two new products during the quarter, with VialArch for bottles expected in the autumn. We are encouraged by the seemingly increasing product release cadence as our investment thesis builds on Gasporox leveraging its existing product platforms and supply chain to enter new package types and geographic markets.
We reiterate our fair value range of SEK9-36 with a base case of SEK18. Gasporox trade at the bottom end of its EV/S valuation range over the past three years and at a steep discount to peers on EV/S for 2024e-2026e despite being close to profitable. Gasporox is on track to achieving its target of sustained positive free cash flow, for which we do not believe the market is crediting the management team. We expect strong earnings and order announcements to catalyse the share. We believe a prolonged period of lackluster profits is the main risk in our thesis.
SEKm | 2022 | 2023 | 2024e | 2025e | 2026e |
Net Sales | 21.4 | 31.4 | 38.2 | 51.6 | 69.6 |
Sales Growth | 36.3% | 46.5% | 21.5% | 35.0% | 35.0% |
EBITDA | -0.90 | 3.6 | 6.8 | 13.1 | 22.4 |
EBIT | -4.2 | -0.58 | 1.5 | 6.9 | 15.3 |
EBIT Margin | -19.7% | -1.8% | 4.0% | 13.4% | 22.0% |
Net Income | -4.4 | -1.2 | 0.79 | 5.5 | 12.1 |
EV/Sales | 4.0 | 3.9 | 2.4 | 1.7 | 1.1 |
EV/EBIT | -20.1 | -215 | 60.4 | 12.8 | 5.2 |
Disclosures and disclaimers
Contents
Estimates versus outcome
Download article